Schizophrenia trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Schizophrenia. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ALKS | Alkermes, Inc. | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Change from baseline in body mass index (BMI) Zscore at week 12 | Phase 3 | Recruiting | Sep 2026 | ≤ 41 d | 2026-08-14 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24 | Phase 4 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Schizophrenia
most recently updated first299 studies match. Showing the first 100 of 299 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)NCT07101094observationalParticipant medication preference as assessed by the Preference of Medication (POM) questionnaire | — | Recruiting | Drug: xanomeline and trospium chloride (X/T) therapy | Schizophrenia | 300 | 2025-09-22 | 2029-01-31 | in 895 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827observationalTreatment titration and switch regimens as described by the prescribing clinician | — | Recruiting | Drug: Xanomeline and trospium chloride (KarXT) | Schizophrenia | 1,500 | 2026-02-26 | 2028-06-20 | in 670 d | 2026-08-19 |
| ALKS | Alkermes, Inc. | $8.3B | Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229Incidence of adverse events | Phase 3 | Enrolling by invitation | Drug: OLZ/SAM | Bipolar I Disorder, Schizophrenia | 236 | 2021-10-22 | Sep 2027 | ≤ 406 d | 2026-08-14 |
| ALKS | Alkermes, Inc. | $8.3B | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Change from baseline in body mass index (BMI) Zscore at week 12 | Phase 3 | Recruiting | Drug: OLZ/SAM, Olanzapine | Schizophrenia, Bipolar I Disorder | 220 | 2022-06-30 | Sep 2026 | ≤ 41 d | 2026-08-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)NCT07288567Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score | Phase 3 | Recruiting | Drug: KarXT · Other: KarXT Matching Placebo | Schizophrenia | 166 | 2026-01-29 | 2029-12-18 | in 1,216 d | 2026-08-13 |
| MPLT | MapLight Therapeutics | $477M | A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647To assess the safety and tolerability of long-term ML-007C-MA administration in adult participants with schizophrenia | Phase 2 | Recruiting | Drug: ML-007C-MA | Schizophrenia | 500 | 2026-03-31 | Feb 2030 | ≤ 1,288 d | 2026-08-13 |
| BTAI | BioXcel Therapeutics Inc | $25M | Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaNCT04010305PANSS-EC Change From Baseline | Phase 1 | Completed | Drug: Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film | Agitation, Schizophrenia | 135 | 2019-05-22 | 2019-07-31actual | — | 2026-08-11 |
| BTAI | BioXcel Therapeutics Inc | $25M | Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaNCT04268303results2023-06-18Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score | Phase 3 | Completed | Drug: Sublingual film containing dexmedetomidine (BXCL501), Placebo Film | Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders | 380 | 2020-01-24 | 2020-05-06actual | — | 2026-08-11 |
| BTAI | BioXcel Therapeutics Inc | $25M | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderNCT05025605Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score | Phase 1 | Recruiting | Drug: BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms, BXCL501 60 Micrograms | Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II | 140 | 2021-08-27 | 2027-07-31 | in 345 d | 2026-08-11 |
| BTAI | BioXcel Therapeutics Inc | $25M | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderNCT06041646results2026-01-02Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score | Phase 4 | Completed | Drug: Sublingual film containing Igalmi | Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders | 29 | 2023-10-02 | 2024-04-29actual | — | 2026-08-11 |
| BTAI | BioXcel Therapeutics Inc | $25M | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total score | Phase 3 | Completed | Drug: BXCL501, Matching Placebo | Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders | 452 | 2022-11-21 | 2025-08-15actual | — | 2026-08-07 |
| BTAI | BioXcel Therapeutics Inc | $25M | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694Informant and Clinician ratings comparison | Phase 2 | Completed | Drug: BXCL501 Sublingual Film | Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation | 33 | 2025-06-19 | 2025-10-07actual | — | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²) | Phase 2 | Recruiting | Drug: Brenipatide, Placebo | Schizophrenia | 450 | 2026-02-10 | Nov 2027 | ≤ 467 d | 2026-08-06 |
| NERV | Minerva Neurosciences | $217M | Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428Change from Baseline to Week 12 in Marder Negative Symptoms Factor Score (NSFS) | Phase 3 | Recruiting | Drug: Roluperidone, risperidone, aripiprazole, olanzapine, Placebo | Negative Symptoms of Schizophrenia | 380 | 2026-04-23 | Dec 2027 | ≤ 498 d | 2026-07-28 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score | Phase 3 | Recruiting | Drug: KarXT · Other: Placebo | Schizophrenia | 250 | 2025-06-10 | 2028-09-23 | in 765 d | 2026-07-27 |
| LBRX | LB Pharmaceuticals Inc. | $1.5B | Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaNCT07363577Change from baseline to Week 6 on the Positive and Negative Syndrome Scale | Phase 3 | Recruiting | Drug: LB-102 (50 mg tablet), LB-102 (100 mg tablet) · Other: Placebo | Schizophrenia | 456 | 2026-03-25 | Jun 2027 | ≤ 314 d | 2026-07-27 |
| LBRX | LB Pharmaceuticals Inc. | $1.5B | 52-week Open Label Safety-Tolerability StudyNCT07369154Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events. | Phase 3 | Recruiting | Drug: LB-102 | Schizophrenia | 900 | 2026-04-23 | Dec 2028 | ≤ 864 d | 2026-07-27 |
| NBIX | Neurocrine Biosciences | $15.7B | Evaluation of NBI-1117570 in Inpatient Adults With SchizophreniaNCT07288333Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35 | Phase 2 | Recruiting | Drug: NBI-1117570, Placebo | Schizophrenia | 120 | 2026-02-16 | Aug 2027 | ≤ 376 d | 2026-07-22 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaNCT07680946Percentage of Participants with at Least 20% Reduction From Baseline in PANSS Total Score | Phase 2 | Recruiting | Drug: Ublituximab | Schizophrenia | 60 | 2026-07-03 | 2028-12-01 | in 834 d | 2026-07-21 |
| MPLT | MapLight Therapeutics | $477M | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total Score | Phase 2 | Completed | Drug: Placebo, ML-007C-MA BID, ML-007C-MA QD | Schizophrenia | 307 | 2025-06-27 | 2026-06-04actual | — | 2026-07-09 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24 | Phase 4 | Recruiting | Drug: Valbenazine | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 50 | 2025-08-29 | Jan 2027 | ≤ 164 d | 2026-06-16 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTNCT07061288Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: KarXT | Schizophrenia | 116 | 2025-09-03 | 2027-06-21 | in 305 d | 2026-06-12 |
| NBIX | Neurocrine Biosciences | $15.7B | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874Number of Participants with Treatment-emergent Adverse Events | Phase 3 | Recruiting | Drug: NBI-1117568 | Schizophrenia | 600 | 2025-07-11 | Dec 2031 | ≤ 1,959 d | 2026-06-05 |
| NBIX | Neurocrine Biosciences | $15.7B | Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNCT07227818Time From Randomization to Relapse | Phase 3 | Recruiting | Drug: NBI-1117568, Placebo | Schizophrenia | 560 | 2025-12-16 | Jul 2029 | ≤ 1,076 d | 2026-06-05 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Effect of KarXT on Urological SafetyNCT07221877Change from baseline in voiding dynamics (Qmax) over time | Phase 4 | Recruiting | Drug: Xanomeline/trospium chloride | Schizophrenia | 60 | 2026-01-20 | 2027-12-30 | in 497 d | 2026-06-03 |
| NBIX | Neurocrine Biosciences | $15.7B | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT07105098Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 | Phase 3 | Recruiting | Drug: NBI-1117568, Placebo | Schizophrenia | 284 | 2025-08-11 | Nov 2027 | ≤ 467 d | 2026-05-15 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT UsersNCT07571148observationalNumber of all-cause and schizophrenia-related healthcare encounters per participant | — | Active, not recruiting | Drug: KarXT (xanomeline and trospium) | Schizophrenia | 6,876 | 2026-01-16 | 2026-03-25actual | — | 2026-05-06 |
| NBIX | Neurocrine Biosciences | $15.7B | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT06963034Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 | Phase 3 | Recruiting | Drug: NBI-1117568, Placebo | Schizophrenia | 284 | 2025-05-08 | Oct 2027 | ≤ 437 d | 2026-03-06 |
| NBIX | Neurocrine Biosciences | $15.7B | Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaNCT05110157Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10 | Phase 3 | Completed | Drug: Placebo, Valbenazine | Schizophrenia | 442 | 2021-11-29 | 2025-02-04actual | — | 2026-02-10 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaNCT07145918Number of Participants with Adverse Events (AEs) | Phase 2 | Recruiting | Drug: Emraclidine, Placebo | Schizophrenia | 268 | 2025-08-04 | Feb 2028 | ≤ 558 d | 2026-02-10 |
| LLY | Eli Lilly and Company | $1.15T | Zyprexa® Relprevv™ Patient Care ProgramNCT01088386observationalIncidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) events | — | Enrolling by invitation | — | Schizophrenia | 4,000 | 2010-03-03 | Jun 2026 | — | 2026-01-28 |
| NBIX | Neurocrine Biosciences | $15.7B | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaNCT05859698results2026-01-16Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24 | Phase 4 | Completed | Drug: Valbenazine | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 59 | 2023-05-09 | 2024-12-27actual | — | 2026-01-16 |
| VNDA | Vanda Pharmaceuticals | $329M | Randomized Withdrawal Study in Patients With SchizophreniaNCT06961968Time to exacerbation of symptoms | Phase 3 | Recruiting | Drug: iloperidone, placebo | Schizophrenia | 400 | 2025-05-14 | Nov 2027 | ≤ 467 d | 2026-01-12 |
| ANRO | Alto Neuroscience | $1.3B | Study of ALTO-101 in Patients With SchizophreniaNCT06502964Theta band activity | Phase 2 | Recruiting | Drug: ALTO-101, Placebo · Device: ALTO-101 Transdermal Delivery System, Placebo Transdermal Delivery System | Schizophrenia, Cognitive Impairment | 82 | 2024-06-11 | Feb 2026 | — | 2025-12-26 |
| ABBV | AbbVie | $457.5B | A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227703results2025-10-28Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score | Phase 2 | Completed | Drug: Emraclidine 15 mg, Emraclidine 30 mg, Placebo | Schizophrenia | 391 | 2022-07-05 | 2024-08-15actual | — | 2025-10-28 |
| ABBV | AbbVie | $457.5B | Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderNCT04578756Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period | Phase 3 | Completed | Drug: Cariprazine Flexible Dose, Cariprazine Flexible Dose | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 310 | 2021-02-01 | 2025-10-06actual | — | 2025-10-27 |
| LBRX | LB Pharmaceuticals Inc. | $1.5B | Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108results2025-10-22Change From Baseline to Week 4 in the PANSS Total Score | Phase 2 | Completed | Drug: LB-102 | Schizophrenia | 359 | 2023-11-29 | 2024-12-04actual | — | 2025-10-22 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaNCT05368558results2025-10-20Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Cariprazine, Placebo | Schizophrenia | 34 | 2022-08-18 | 2024-09-20actual | — | 2025-10-20 |
| VNDA | Vanda Pharmaceuticals | $329M | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsNCT06494397Bioequivalence between VHX-896 tablets relative to iloperidone tablets | Phase 1 | Completed | Drug: VHX-896 and iloperidone, Iloperidone and VHX-896 | Schizophrenia, Bipolar I Disorder | 26 | 2024-07-11 | 2024-10-24actual | — | 2025-09-19 |
| ABBV | AbbVie | $457.5B | A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227690results2025-09-17Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score | Phase 2 | Completed | Drug: Placebo, Emraclidine 10 mg, Emraclidine 30 mg | Schizophrenia | 385 | 2022-06-30 | 2024-08-23actual | — | 2025-09-17 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586results2025-08-24Treatment Emergent Adverse Events | Phase 3 | Terminated | Drug: Pimavanserin | Schizophrenia | 995 | Jan 2017 | 2024-04-30actual | — | 2025-08-24 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982results2025-04-01Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26 | Phase 3 | Completed | Drug: Pimavanserin, Placebo | Schizophrenia | 454 | 2020-08-05 | 2024-01-25actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: CVL-231 30 mg | Schizophrenia | 700 | 2022-09-02 | 2025-06-25actual | — | 2025-07-28 |
| NBIX | Neurocrine Biosciences | $15.7B | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaNCT05545111Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6 | Phase 2 | Completed | Drug: NBI-1117568, Placebo | Schizophrenia | 210 | 2022-10-04 | 2024-07-10actual | — | 2025-07-11 |
| NBIX | Neurocrine Biosciences | $15.7B | Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaNCT05182476Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) Composite Score | Phase 2 | Terminatedsponsor's stated reason: Failed to meet the primary endpoint | Drug: Placebo, Luvadaxistat | Schizophrenia | 216 | 2021-12-07 | 2024-06-28actual | — | 2025-07-02 |
| AVXL | Anavex Life Sciences Corp. | $297M | A Study of ANAVEX3-71 in Adults With SchizophreniaNCT06245213Single Dose Maximum Observed Plasma Concentration (Cmax) | Phase 2 | Active, not recruiting | Drug: ANAVEX3-71 oral capsules, Placebo oral capsules | Schizophrenia | 71 | 2024-03-15 | 2025-06-30 | — | 2025-05-04 |
| VNDA | Vanda Pharmaceuticals | $329M | Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsNCT05648591Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period. | Phase 4 | Recruiting | Drug: Iloperidone | Schizophrenia, Bipolar I Disorder | 100 | 2023-05-24 | 2026-03-31 | — | 2025-03-04 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | ACP-104 in Acutely Psychotic Subjects With SchizophreniaNCT00490516PANSS | Phase 2 | Completed | Drug: ACP-104, ACP-104, Placebo | Schizophrenia | 247 | Jun 2007 | Feb 2008actual | — | 2025-01-20 |
| RVPH | Reviva Pharmaceuticals | $6M | Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335Double Blind Safety and Efficacy of Brilaroxazine (RP5063) | Phase 3 | Recruiting | Drug: Brilaroxazine · Other: Placebo | Schizophrenia | 690 | 2022-01-24 | Feb 2025 | — | 2024-12-19 |
| VNDA | Vanda Pharmaceuticals | $329M | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202results2024-12-13Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score | Phase 3 | Completed | Drug: Iloperidone, Ziprasidone, Placebo | Schizophrenia | 593 | 2005-11-18 | 2006-09-26actual | — | 2024-12-13 |
| NBIX | Neurocrine Biosciences | $15.7B | Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaNCT05654870Change in Positive and Negative Syndrome Scale (PANSS) Total Score from Baseline to Week 10 | Phase 3 | Terminatedsponsor's stated reason: Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision. | Drug: Valbenazine, Placebo | Schizophrenia | 8 | 2023-01-05 | 2023-11-08actual | — | 2024-11-12 |
| ALKS | Alkermes, Inc. | $8.3B | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757results2024-09-26Incidence of Adverse Events | Phase 3 | Completed | Drug: ALKS 3831 | Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder | 523 | 2017-06-15 | 2023-09-06actual | — | 2024-09-26 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)NCT00151424Change in total Positive and Negative Syndrome Scale (PANSS) score at endpoint (6-week double-blind or last assessment after baseline) from baseline | Phase 3 | Completed | Drug: asenapine, Placebo, Olanzapine | Schizophrenia | 277 | 2005-02-15 | 2006-01-06actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)NCT00156104Improvement in schizophrenia (change in total PANSS score) from baseline to endpoint (LOCF/MMRM) | Phase 3 | Completed | Drug: Asenapine, Asenapine, Haloperidol · Other: Placebo arm | Schizophrenia | 460 | 2005-07-01 | 2006-08-18actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)NCT00156117Change in total PANSS score at endpoint (6-week double-blind or last assessment after baseline) from baseline | Phase 3 | Completed | Drug: asenapine, Placebo, olanzapine | Schizophrenia | 417 | 2005-05-12 | 2006-04-28actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)NCT00212784Change in total PANSS score at endpoint (52-week double-blind or last assessment after baseline) from baseline | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia, Schizoaffective Disorder | 1,225 | 2003-09-04 | 2006-03-15actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)NCT00212836Changes from baseline at 6-months in Negative symptoms of schizophrenia measured by the Negative Symptoms Assessment (NSA) scale | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia | 481 | 2005-04-21 | 2007-06-15actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)NCT01098110results2015-04-17Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. | Phase 3 | Completed | Drug: Asenapine 5 mg, Asenapine 10 mg, Placebo | Schizophrenia | 532 | 2010-05-25 | 2014-04-14actual | — | 2024-06-20 |
| OGN | Organon and Co | $3.6B | A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)NCT01617187results2015-08-31Change From Baseline in PANSS Total Score at Day 42 | Phase 3 | Completed | Drug: Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine | Schizophrenia | 360 | 2012-12-04 | 2014-08-11actual | — | 2024-06-18 |
| OGN | Organon and Co | $3.6B | Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)NCT01142596results2016-05-18Percentage of Participants in Categories of Change in Weight From Study P06124 Baseline to Final Assessment | Phase 3 | Completed | Drug: Asenapine, Placebo | Schizophrenia | 201 | 2010-05-25 | 2015-04-22actual | — | 2024-05-28 |
| OGN | Organon and Co | $3.6B | Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)NCT01244828results2015-08-26Change From Baseline in Weight at Week 52 | Phase 3 | Completed | Drug: Asenapine | Schizophrenia | 157 | 2011-04-05 | 2014-08-21actual | — | 2024-05-28 |
| OGN | Organon and Co | $3.6B | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)NCT01206517results2012-12-21Maximum Plasma Concentration (Cmax) of Asenapine | Phase 1 | Completed | Drug: Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg | Schizophrenia, Bipolar I Disorder | 30 | 2010-07-18 | 2011-08-04actual | — | 2024-05-23 |
| OGN | Organon and Co | $3.6B | Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)NCT01190267results2014-08-06Number of Participants With a Treatment-Emergent Adverse Event (AE) During Extension Study | Phase 3 | Completed | Drug: asenapine | Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated | 204 | 2010-09-28 | 2013-10-07actual | — | 2024-05-22 |
| OGN | Organon and Co | $3.6B | Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)NCT01190254results2014-06-06Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 | Phase 3 | Completed | Drug: asenapine 2.5 mg, asenapine 5.0 mg, placebo | Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated | 306 | 2010-09-28 | 2013-03-10actual | — | 2024-05-21 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With SchizophreniaNCT03359785results2024-02-28Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8 | Phase 2 | Completed | Drug: Luvadaxistat, Matching Placebo | Schizophrenia | 31 | 2018-01-10 | 2020-12-21actual | — | 2024-02-28 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of SchizophreniaNCT03382639results2024-02-28Change From Baseline on the PANSS NSFS at Week 12 | Phase 2 | Completed | Drug: Luvadaxistat, Placebo | Schizophrenia | 256 | 2018-01-04 | 2020-12-29actual | — | 2024-02-28 |
| VNDA | Vanda Pharmaceuticals | $329M | Relapse Prevention Study in Patients With SchizophreniaNCT01291511results2023-07-17Time to Relapse or Impending Relapse | Phase 3 | Completed | Drug: Iloperidone, Placebo | Schizophrenia | 635 | Feb 2011 | Mar 2014actual | — | 2023-07-17 |
| VNDA | Vanda Pharmaceuticals | $329M | A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of SchizophreniaNCT04712734Pharmacokinetics of iloperidone and its metabolites following repeat-dosing of iloperidone given as a long-acting injection. | Phase 1 | Completed | Drug: Iloperidone | Schizophrenia | 42 | 2021-01-13 | 2022-08-30actual | — | 2023-06-29 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456results2023-06-15Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score | Phase 2 | Terminatedsponsor's stated reason: This study was terminated based on a business decision by the Sponsor. | Drug: GWP42003-P, Placebo | Schizophrenia | 95 | 2020-08-18 | 2022-03-16actual | — | 2023-06-15 |
| NERV | Minerva Neurosciences | $217M | Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of SchizophreniaNCT03397134results2023-04-28Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) | Phase 3 | Completed | Drug: Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg | Negative Symptoms of Schizophrenia | 515 | 2017-12-15 | 2020-05-26actual | — | 2023-04-28 |
| ALKS | Alkermes, Inc. | $8.3B | Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)NCT03919994observationalSchizophrenia disease history | — | Completed | — | Schizophrenia | 338 | 2019-03-28 | 2023-01-04actual | — | 2023-02-02 |
| ALKS | Alkermes, Inc. | $8.3B | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderNCT03187769results2023-01-19Percent Change From Baseline in Body Weight at Week 12 | Phase 3 | Completed | Drug: ALKS 3831, Olanzapine | Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder | 426 | 2017-06-08 | 2021-12-01actual | — | 2023-01-19 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic DisorderNCT02006628results2019-07-26Change From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score | Phase 2 | Completed | Drug: Placebo, GWP42003 | Schizophrenia, Schizophrenia-related Psychotic Disorder | 88 | 2014-02-25 | 2015-01-08actual | — | 2022-09-28 |
| LBRX | LB Pharmaceuticals Inc. | $1.5B | Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy VolunteersNCT04588129Brain Receptor Occupancy as Measured by Positron Emission Tomography | Phase 1 | Completed | Drug: LB-102 | Schizophrenia | 16 | 2021-01-05 | 2021-09-17actual | — | 2022-05-04 |
| ABBV | AbbVie | $457.5B | Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaNCT03593213results2022-03-08Time to First Relapse During Double-blind Treatment Period | Phase 3 | Terminatedsponsor's stated reason: FDA Released Allergan from this post marketing requirement | Drug: Cariprazine, Placebo | Schizophrenia | 587 | 2018-07-30 | 2021-02-11actual | — | 2022-04-11 |
| OGN | Organon and Co | $3.6B | Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)NCT00156091To assess long-term safety including overall symptoms (AEs; SAEs); Vital signs; ISST; EPS; and maintenance of effect; for asenapine with haloperidol control. | Phase 3 | Completed | Drug: Olanzapine, Asenapine · Other: Placebo | Schizophrenia | 260 | Apr 2005 | Jun 2007actual | — | 2022-02-16 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)NCT00212771Change in total PANSS score at endpoint | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia, Schizoaffective Disorder | 440 | Sep 2004 | Sep 2006actual | — | 2022-02-16 |
| OGN | Organon and Co | $3.6B | 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)NCT00174265results2010-07-05Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia | 196 | Jul 2005 | Apr 2009actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)NCT00265343results2010-02-23Long-term Change in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia | 306 | Dec 2005 | Dec 2007actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)NCT01101464results2010-10-13Pharmacokinetic Parameter of Maximum Plasma Concentration (Cmax) of Two Differing Tablet Strengths (3 x 5 mg and 1 x 15 mg) of Sublingually Administered Org 5222 (Asenapine) | Phase 2 | Completed | Drug: Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg | Schizophrenia, Schizoaffective Disorder | 8 | Oct 2002 | Dec 2002actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)NCT00145496results2010-03-25Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score | Phase 3 | Completed | Drug: Asenapine, Olanzapine | Schizophrenia | 468 | Dec 2004 | Nov 2008actual | — | 2022-02-08 |
| OGN | Organon and Co | $3.6B | To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)NCT00150176results2010-05-28Time to Relapse or an Impending Relapse | Phase 3 | Completed | Drug: Asenapine - Open Label, Placebo - Double Blind, Asenapine - Double Blind | Schizophrenia | 831 | Apr 2005 | Jun 2008actual | — | 2022-02-08 |
| OGN | Organon and Co | $3.6B | Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)NCT00156065results2010-04-07Loss of Effect Over Time | Phase 3 | Completed | Drug: Haloperidol, Asenapine, Asenapine | Schizophrenia | 187 | Sep 2005 | Sep 2007actual | — | 2022-02-08 |
| OGN | Organon and Co | $3.6B | Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)NCT01495741observationalNumber of Participants with Bipolar Disorder with Identified and Potential Clinically Important Risks | — | Completed | — | Bipolar Disorder, Schizophrenia | 42 | 2013-07-01 | 2017-12-18actual | — | 2022-02-04 |
| BIIB | Biogen | $31.4B | Multiple Ascending Doses of PF-04958242 in Subjects With Stable SchizophreniaNCT02332798results2016-06-14Maximum Observed Plasma Concentration (Cmax) (Single Dose) | Phase 1 | Completed | Drug: PF-04958242, Placebo | Schizophrenia | 39 | 2015-01-06 | 2015-04-15actual | — | 2021-10-25 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderNCT02161718results2021-10-08Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS) | Phase 2 | Completed | Drug: Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine | Schizophrenia, Alcohol Use Disorder | 300 | May 2014 | 2017-01-11actual | — | 2021-10-08 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of ALKS 3831 in Adults With SchizophreniaNCT01903837results2021-09-08Absolute Change in Total Positive and Negative Syndrome Scale (PANSS) Score | Phase 2 | Completed | Drug: Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine | Schizophrenia | 347 | Jun 2013 | Dec 2014actual | — | 2021-10-06 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic PatientsNCT00781794electroencephalogram | Phase 1 | Withdrawn | Drug: NSA-789 at 2 different doses | Schizophrenia | 0 | Jan 2009 | Aug 2009 | — | 2021-08-20 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective DisorderNCT00892021Safety as measured by adverse events, monitoring of safety variables (ECGs, vital signs, laboratory test results) | Phase 1 | Withdrawn | Drug: NSA-789, Placebo | Schizophrenia | 0 | May 2009 | Oct 2009 | — | 2021-08-20 |
| ALKS | Alkermes, Inc. | $8.3B | A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaNCT02873208results2021-07-21Number of Subjects With Adverse Events | Phase 3 | Completed | Drug: ALKS 3831 | Schizophrenia | 266 | 2016-08-07 | 2019-10-17actual | — | 2021-07-21 |
| NBIX | Neurocrine Biosciences | $15.7B | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyNCT02748694results2021-03-01Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: TAK-041, TAK-041 Placebo | Healthy Volunteers, Schizophrenia | 114 | 2016-05-09 | 2019-09-22actual | — | 2021-03-19 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)NCT02970305results2020-12-22Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total Score | Phase 2 | Completed | Drug: Pimavanserin, Placebo | Schizophrenia | 403 | 2016-11-04 | 2019-10-16actual | — | 2020-12-22 |
| LBRX | LB Pharmaceuticals Inc. | $1.5B | Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy AdultsNCT04187560Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) | Phase 1 | Completed | Drug: LB-102 | Schizophrenia | 64 | 2020-01-22 | 2020-07-01actual | — | 2020-12-10 |
| HLUN-B.CO | H. Lundbeck A/S | — | Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With SchizophreniaNCT02892422results2020-10-26Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) | Phase 3 | Completed | Drug: Lu AF35700 | Schizophrenia | 528 | Aug 2016 | 2019-10-10actual | — | 2020-10-26 |
| NVS | Novartis | — | A Long Term Study of Clozapine in Patients With Treatment-resistant SchizophreniaNCT00154258Adverse events during the long term treatment (until NDA approval) | Phase 2 | Completed | Drug: Clozapine | Schizophrenia | 19 | Apr 2001 | Dec 2009actual | — | 2020-09-24 |
| HLUN-B.CO | H. Lundbeck A/S | — | Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With SchizophreniaNCT03793712Change in Negative Symptom Scale (BNSS) total score | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy based on interim analysis | Drug: Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day), Placebo | Schizophrenia | 168 | 2018-12-27 | 2020-08-20actual | — | 2020-09-23 |
| HLUN-B.CO | H. Lundbeck A/S | — | Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative SymptomsNCT03929497Number of participants with Treatment-Emergent Adverse Events | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy based on the interim analysis in the 17972A study | Drug: Lu AF11167 | Schizophrenia | 96 | 2019-04-22 | 2020-09-01actual | — | 2020-09-23 |
| ALKS | Alkermes, Inc. | $8.3B | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaNCT03345979results2020-08-11Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 | Phase 3 | Completed | Combination product: Aripiprazole Lauroxil · Drug: Paliperidone Palmitate | Schizophrenia | 200 | 2017-11-15 | 2019-03-12actual | — | 2020-08-11 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)NCT02970292results2020-06-17Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score | Phase 3 | Completed | Drug: Pimavanserin, Placebo | Schizophrenia | 396 | 2016-10-26 | 2019-05-28actual | — | 2020-06-17 |
| HLUN-B.CO | H. Lundbeck A/S | — | Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700NCT02333487results2020-05-12Emax D1 Dopamine | Phase 1 | Completed | Drug: Lu AF35700 | Schizophrenia | 22 | 2014-12-30 | 2016-02-11actual | — | 2020-05-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Schizophrenia is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Schizophrenia
- Schizophrenic Disorders
- Schizophreniform Disorders
- Schizophreniform Disorder
- Negative Symptoms of Schizophrenia
- Schizophrenia or Schizoaffective Disorder
- Schizophrenia, Disorganized
- Schizophrenia, Paranoid
- Schizophrenia, Undifferentiated
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Schizophrenia” (a text search, wider than this page)